Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Non Operating Income (2021 - 2025)

Coeptis Therapeutics Holdings has reported Non Operating Income over the past 5 years, most recently at -$393932.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$393932.0 for Q4 2025, down 142.14% from a year ago — trailing twelve months through Dec 2025 was -$1.0 million (down 472.69% YoY), and the annual figure for FY2025 was $7004.0, up 142.59%.
  • Non Operating Income for Q4 2025 was -$393932.0 at Coeptis Therapeutics Holdings, up from -$421735.0 in the prior quarter.
  • Over the last five years, Non Operating Income for COEPW hit a ceiling of $14.2 million in Q1 2021 and a floor of -$3.5 million in Q1 2022.
  • Median Non Operating Income over the past 5 years was -$79502.5 (2022), compared with a mean of $364228.6.
  • Biggest five-year swings in Non Operating Income: skyrocketed 4715.45% in 2023 and later plummeted 4297.69% in 2025.
  • Coeptis Therapeutics Holdings' Non Operating Income stood at -$1.6 million in 2021, then skyrocketed by 105.99% to $98701.0 in 2022, then plummeted by 494.75% to -$389618.0 in 2023, then skyrocketed by 58.24% to -$162690.0 in 2024, then tumbled by 142.14% to -$393932.0 in 2025.
  • The last three reported values for Non Operating Income were -$393932.0 (Q4 2025), -$421735.0 (Q3 2025), and -$338460.0 (Q2 2025) per Business Quant data.